IO Biotech downgraded by Morgan Stanley with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for IOBT
Across the 6 sessions after earlier IOBT headlines, the stock closed higher 4 times and lower 2 times, with a median move of 4.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IOBT | SPY |
|---|---|---|---|
| Dec 16, 2025 | IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications | -2.3% | -0.3% |
| Nov 26, 2025 | IO Biotech Announces Participation in Upcoming December Investor Conferences | +0.9% | +0.7% |
| Nov 14, 2025 | IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights | +1.7% | -0.0% |
| Nov 12, 2025 | IO Biotech Announces Participation in Upcoming Investor Conferences | -6.0% | +0.1% |
| Nov 7, 2025 | IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | +7.0% | +0.1% |
| Oct 20, 2025 | IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 | +25.2% | +1.0% |
Quantisnow market dataNASDAQ
IOBT
IO Biotech Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for IOBT
Full IOBT profile on Quantisnow Follow IOBT and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time